4552 Stock Overview
Engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 6/6 |
JCR Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥586.00 |
| 52 Week High | JP¥1,567.00 |
| 52 Week Low | JP¥586.00 |
| Beta | 0.0086 |
| 1 Month Change | -27.74% |
| 3 Month Change | -35.32% |
| 1 Year Change | -59.64% |
| 3 Year Change | -82.08% |
| 5 Year Change | -65.68% |
| Change since IPO | 163.37% |
Recent News & Updates
Shareholder Returns
| 4552 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -6.7% | -1.7% | 0.05% |
| 1Y | -59.6% | 1.1% | 24.3% |
Return vs Industry: 4552 underperformed the JP Pharmaceuticals industry which returned 2.3% over the past year.
Return vs Market: 4552 underperformed the JP Market which returned 24.8% over the past year.
Price Volatility
| 4552 volatility | |
|---|---|
| 4552 Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 7.9% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4552's share price has been volatile over the past 3 months.
Volatility Over Time: 4552's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1975 | 879 | Shin Ashida | www.jcrpharm.co.jp |
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease.
JCR Pharmaceuticals Co., Ltd. Fundamentals Summary
| 4552 fundamental statistics | |
|---|---|
| Market cap | JP¥73.13b |
| Earnings (TTM) | JP¥5.51b |
| Revenue (TTM) | JP¥42.87b |
13.3x
P/E Ratio1.7x
P/S RatioIs 4552 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4552 income statement (TTM) | |
|---|---|
| Revenue | JP¥42.87b |
| Cost of Revenue | JP¥11.62b |
| Gross Profit | JP¥31.25b |
| Other Expenses | JP¥25.74b |
| Earnings | JP¥5.51b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 44.13 |
| Gross Margin | 72.90% |
| Net Profit Margin | 12.85% |
| Debt/Equity Ratio | 41.3% |
How did 4552 perform over the long term?
See historical performance and comparison